Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Free Cash Flow (2016 - 2025)

Acro Biomedical has reported Free Cash Flow over the past 10 years, most recently at -$25377.0 for Q4 2025.

  • Quarterly results put Free Cash Flow at -$25377.0 for Q4 2025, down 141.34% from a year ago — trailing twelve months through Dec 2025 was -$196302.0 (down 435.0% YoY), and the annual figure for FY2025 was -$196302.0, down 435.0%.
  • Free Cash Flow for Q4 2025 was -$25377.0 at Acro Biomedical, up from -$54410.0 in the prior quarter.
  • Over the last five years, Free Cash Flow for ACBM hit a ceiling of $432770.0 in Q2 2021 and a floor of -$345777.0 in Q2 2022.
  • Median Free Cash Flow over the past 5 years was -$11590.5 (2022), compared with a mean of -$4829.3.
  • Biggest five-year swings in Free Cash Flow: soared 3228.07% in 2022 and later tumbled 1411.59% in 2024.
  • Acro Biomedical's Free Cash Flow stood at -$60506.0 in 2021, then surged by 82.53% to -$10568.0 in 2022, then decreased by 19.35% to -$12613.0 in 2023, then increased by 16.63% to -$10515.0 in 2024, then plummeted by 141.34% to -$25377.0 in 2025.
  • The last three reported values for Free Cash Flow were -$25377.0 (Q4 2025), -$54410.0 (Q3 2025), and -$93984.0 (Q2 2025) per Business Quant data.